Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - Vera Therapeutics, Inc. is a late clinical-stage biotechnology company focused on developing transformative treatments for serious immunological diseases [3] - The company's mission is to advance treatments targeting the source of immunological diseases to change the standard of care for patients [3] Product Pipeline - Vera's lead product candidate is atacicept, a fusion protein administered as a subcutaneous injection once weekly, which blocks B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL) [3] - Atacicept is aimed at treating autoimmune diseases such as IgAN (Berger's disease) and lupus nephritis by reducing autoantibodies [3] - The company is also developing MAU868, a monoclonal antibody designed to neutralize BK virus (BKV) infections, particularly in kidney transplant settings [3] - Vera retains all global developmental and commercial rights to both atacicept and MAU868 [3] Upcoming Events - The management team will present at the 43rd Annual J.P. Morgan Healthcare Conference from January 12 to 16, 2025, and will participate in one-on-one investor meetings [1] - The presentation is scheduled for January 13, 2025, at 4:30 PM PST, with a webcast available for viewing [2]